BNP/CALL/ABBVIE/200/0.1/19.12.25 Share Price

DE000PC4AE74

Market Closed - Boerse Frankfurt Warrants 01:20:31 15/06/2024 am IST
0.88 ^EUR	+11.39%

Current month	+49.15%
1 month	+35.38%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ABBVIE INC.

Latest news about ABBVIE INC.

AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer	15/06	MT
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer	15/06	PR
AbbVie inks immune disorder drug licensing deal with China's FutureGen	13/06	RE
AbbVie, FutureGen in License Pact for Inflammatory Bowel Disease Drug	13/06	DJ

More news

Quotes 5-day view

Date	Price	Change
14/24/14	0.88	+11.39%
13/24/13	0.79	+2.60%
12/24/12	0.77	-9.41%
11/24/11	0.85	-8.60%
10/24/10	0.93	+4.49%

Real-time Boerse Frankfurt Warrants

Last update June 15, 2024 at 01:20 am IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ABBVIE INC.
Issuer	BNP Paribas
WKN	PC4AE7
ISIN	DE000PC4AE74
Date issued	31/01/2024
Strike	200 $
Maturity	19/12/2025 (551 Days)
Parity	10 : 1
Emission price	0.66 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.56 €
Lowest since issue	0.45 €
Spread	0.02 €
Spread %	2.22%

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

More about the company